RT Journal Article SR Electronic T1 Hyaluronan is abundant in COVID-19 respiratory secretions JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.09.11.20191692 DO 10.1101/2020.09.11.20191692 A1 Gernot Kaber A1 Michael J. Kratochvil A1 Elizabeth B. Burgener A1 Egan L. Peltan A1 Graham Barlow A1 Samuel Yang A1 Mark R. Nicolls A1 Vinicio A. de Jesus Perez A1 Joelle Rosser A1 Andrew J. Wardle A1 Anissa Kalinowski A1 Michael G. Ozawa A1 Donald P. Regula A1 Nadine Nagy A1 Sarah C. Heilshorn A1 Carlos E. Milla A1 Angela J. Rogers A1 Paul L. Bollyky YR 2020 UL http://medrxiv.org/content/early/2020/09/11/2020.09.11.20191692.abstract AB COVID-19 respiratory infections are associated with copious, adherent respiratory secretions that prolong chronic ventilation and contribute to the morbidity and mortality caused by the disease. We hypothesized that hyaluronan, an extracellular matrix glycosaminoglycan produced at sites of active inflammation that promotes edema in other settings, might be a component of these secretions. To interrogate this, we examined the respiratory secretions collected from eight intubated patients with COVID-19, six control patients with cystic fibrosis (CF), a different respiratory disease also associated with thick adherent secretions, and eight healthy controls. In this sample set we found that hyaluronan content is increased approximately 20-fold in both CF and COVID-19 patients compared to healthy controls. The hyaluronan in COVID-19 samples was comprised of low-molecular weight fragments, the hyaluronan form most strongly linked with pro-inflammatory functions. Hyaluronan is similarly abundant in histologic sections from cadaveric lung tissue from COVID-19 patients. These findings implicate hyaluronan in the thick respiratory secretions characteristic of COVID-19 infection. Therapeutic strategies targeting hyaluronan should be investigated further for potential use in patients with COVID-19.Competing Interest StatementThe authors have filed a patent on the use of 4-methylumbelliferone, an inhibitor of hyaluronan synthesis in acute respiratory distress syndrome and COVID-19 infection.Funding StatementThis research program is supported by a grant from the Stanford Innovative Medicines Accelerator program. The Stanford ICU Biobank and A.J.R. are funded by NIH/ NHLBI K23 HL125663. A.R. was supported by NIH grant T32 AI007502-23. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Stanford University IRBAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll primary data is available upon request.4-MU4-methylumbelliferoneARDSacute respiratory distress syndrome CF cystic fibrosisHAhyaluronanHLFhuman lung fibroblasts